Zai Lab's ZL-2301 shows encouraging action in mid-stage liver cancer study [Seeking Alpha]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Seeking Alpha
Interim data from a Phase 2 clinical trial evaluating Zai Lab's (NASDAQ: ZLAB ) ZL-2301 (brivanib) in Chinese patients with previously treated advanced hepatocellular carcinoma (HCC) showed a treatment effect and manageable safety profile. The results were presented at the Annual Meeting of the Chinese Society of Clinical Oncology in Xiamen. 90 patients were enrolled to receive oral doses of either 800 mg of ZL-2301 once-daily or 400 mg twice-daily. The co-primary endpoints are disease control rate (DCR) (responders + those with stable cancer) and time-to-disease progression (TTP). On a preliminary basis, the DCRs at week 12 in the 800 mg and 400 mg cohorts were 41.7% and 35.9%, respectively. TTP was 4.2 months and 2.8 months, respectively. On the safety front, ZL-2301 was relatively well-tolerated with a toxicity profile in line with other VEGFR inhibitors. The company says it also plans to conduct a study in HCC evaluating the combination of ZL-2301 and a PD-1 inhibi
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesBusiness Wire
- Novocure Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Zai Lab Limited's (NASDAQ:ZLAB) Profit Outlook [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 11/7/23 - Beat
ZLAB
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 4/29/24 - Form ARS
- ZLAB's page on the SEC website